T1	Claim 1 136	Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC).
T2	Premise 876 998	Overall mean reductions in combined pain and opioid analgesic intake were greater for suramin plus HC (rank sum P =.0001).
T3	Premise 999 1113	Pain response was achieved in a higher proportion of patients receiving suramin than placebo (43% v 28%; P =.001),
T4	Premise 1118 1207	duration of response was longer for suramin responders (median, 240 v 69 days; P =.0027).
T5	Premise 1208 1305	Time to disease progression was longer (relative risk = 1.5; 95% confidence interval, 1.2 to 1.9)
T6	Premise 1310 1440	the proportion of patients with a greater than 50% decline in PSA was higher (33% v 16%; P =.01) in patients who received suramin.
T7	Premise 1441 1523	Neither quality of life nor performance status was decreased by suramin treatment,
T8	Premise 1528 1557	overall survival was similar.
T9	Premise 1558 1647	Most adverse events were of mild or moderate intensity and were easily managed medically.
T10	Claim 1648 1817	Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC.
R1	Support Arg1:T2 Arg2:T10	
R2	Support Arg1:T9 Arg2:T10	
R3	Support Arg1:T3 Arg2:T10	
R4	Support Arg1:T4 Arg2:T10	
R5	Support Arg1:T5 Arg2:T10	
R6	Support Arg1:T6 Arg2:T10	
